STOCK TITAN

Glaukos Corporation (GKOS) 10-K Filings

GKOS NYSE

Here are the 10-K annual reports from Glaukos Corporation (GKOS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow GKOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GKOS filings page.

Rhea-AI Summary

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on glaucoma, corneal disorders and retinal disease. Its core products include the iStent micro‑scale glaucoma devices, iDose TR long‑duration intracameral implant approved in December 2023, and Photrexa/iLink corneal cross‑linking therapies.

The FDA approved Epioxa iLink epi‑on for keratoconus in October 2025, with commercial launch planned in the first half of 2026. In 2025, about 83% of net sales came from glaucoma products (iStent family, iDose TR and accessories) and 17% from iLink therapies. The company is advancing multiple platforms, including iLution transdermal creams and Retinal XR sustained‑release intravitreal drugs, and invests heavily in R&D and international expansion.

Key risks highlighted include dependence on successful commercialization of iDose TR and Epioxa, exposure to macroeconomic and geopolitical volatility, manufacturing and supply disruptions, ongoing operating losses since inception, complex global regulatory and reimbursement regimes, cybersecurity and data‑privacy obligations, and intense competition from larger ophthalmic device and drug companies.